Medpace Holdings, Inc. logo
Medpace Holdings, Inc. (MEDP)
Compare

Medpace Holdings, Inc. (MEDP) Earnings Yield: 3.45%

Is Medpace Holdings, Inc.’s earnings yield high or low?

Medpace Holdings, Inc.'s earnings yield of 3.45% is 10% above its 5-year average of 3.13%, around the middle of its 5-year range (2.12%–4.64%).

As of Wednesday, June 17, 2026. 13.08% above its 12-month average of 3.05%.

MEDP Earnings Yield Chart

MEDP Earnings Yield
3.45%-20.69% 1Y
Zoom

MEDP Average Earnings Yield Chart

MEDP Current vs Average Earnings Yield Chart

MEDP Earnings Yield Metrics

EARNINGS YIELD

3.45%

EARNINGS YIELD AVG TTM

3.05%

EARNINGS YIELD AVG 3Y

3.12%

EARNINGS YIELD AVG 5Y

3.13%

EARNINGS YIELD AVG 10Y

2.88%

EARNINGS YIELD AVG 15Y

N/A

EARNINGS YIELD AVG 20Y

N/A

CURRENT VS TTM AVG

+13.08%

CURRENT VS 3Y AVG

+10.62%

CURRENT VS 5Y AVG

+10.20%

CURRENT VS 10Y AVG

+19.93%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

MEDP Competitors' Earnings Yield

NAMEMARKET CAPEARNINGS YIELDTTM3Y5Y
Medpace Holdings, Inc. (MEDP)$13.18B3.45%3.05%3.12%3.13%
The Cooper Companies, Inc. (COO)vs ›$13.14B1.75%2.74%2.25%12.65%
Solventum Corporation (SOLV)vs ›$13.26B10.67%8.18%8.17%8.17%
DaVita Inc. (DVA)vs ›$13.46B4.76%7.11%6.45%6.99%
Align Technology, Inc. (ALGN)vs ›$12.86B3.32%3.52%2.68%2.48%
Revvity, Inc. (RVTY)vs ›$11.29B2.07%2.32%3.16%3.75%
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37BN/A3.00%10.30%8.48%
Baxter International Inc. (BAX)vs ›$10.19BN/A10.19%8.29%5.38%
Hologic, Inc. (HOLX)vs ›$16.97B3.16%3.63%3.48%5.61%
Charles River Laboratories International, Inc. (CRL)vs ›$8.90BN/A3.32%3.92%3.29%

Earnings Yield vs P/E Ratio

Earnings Yield

3.45%

EPS ÷ Price

P/E Ratio

29.0

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

  • It expresses earnings relative to share price as a percentage
  • It can be compared with FCF yield and dividend yield
  • It can be compared with bond yields because both are percentages
  • It is mathematically the inverse of the P/E ratio

Medpace Holdings, Inc. Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Medpace Holdings, Inc. Earnings Yield FAQ

What is the earnings yield for Medpace Holdings, Inc. (MEDP)?
The earnings yield for MEDP stock is 3.45%.
Is Medpace Holdings, Inc.'s earnings yield high or low?
Medpace Holdings, Inc.'s earnings yield of 3.45% is 10% above its 5-year average of 3.13%, around the middle of its 5-year range (2.12%–4.64%).
What is the TTM average earnings yield for Medpace Holdings, Inc. (MEDP)?
The TTM average earnings yield for MEDP stock is 3.05%.
What is the 3Y average earnings yield for Medpace Holdings, Inc. (MEDP)?
The 3Y average earnings yield for MEDP stock is 3.12%.
What is the 5Y average earnings yield for Medpace Holdings, Inc. (MEDP)?
The 5Y average earnings yield for MEDP stock is 3.13%.
What is the 10Y average earnings yield for Medpace Holdings, Inc. (MEDP)?
The 10Y average earnings yield for MEDP stock is 2.88%.

Medpace Holdings, Inc. Earnings Yield History

DATEEARNINGS YIELD
2026-06-163.45%
2026-06-153.40%
2026-06-123.41%
2026-06-113.35%
2026-06-103.42%
2026-06-093.41%
2026-06-083.48%
2026-06-053.51%
2026-06-043.47%
2026-06-033.53%
2026-06-023.57%
2026-06-013.53%
2026-05-293.56%
2026-05-283.55%
2026-05-273.72%
2026-05-263.71%
2026-05-223.68%
2026-05-213.70%
2026-05-203.77%
2026-05-193.79%
2026-05-183.79%
2026-05-153.83%
2026-05-143.80%
2026-05-133.76%
2026-05-123.79%
2026-05-113.82%
2026-05-083.76%
2026-05-073.71%
2026-05-063.73%
2026-05-053.70%
2026-05-043.82%
2026-05-013.81%
2026-04-303.80%
2026-04-293.85%
2026-04-283.89%
2026-04-273.78%
2026-04-243.88%
2026-04-234.05%
2026-04-223.01%
2026-04-212.97%
2026-04-202.90%
2026-04-172.94%
2026-04-162.97%
2026-04-152.95%
2026-04-142.94%
2026-04-133.05%
2026-04-103.10%
2026-04-093.05%
2026-04-082.94%
2026-04-073.01%
2026-04-063.09%
2026-04-023.07%
2026-04-013.13%
2026-03-313.19%
2026-03-303.33%
2026-03-273.39%
2026-03-263.28%
2026-03-253.28%
2026-03-243.32%
2026-03-233.35%
2026-03-203.38%
2026-03-193.32%
2026-03-183.37%
2026-03-173.36%
2026-03-163.37%
2026-03-133.40%
2026-03-123.45%
2026-03-113.21%
2026-03-103.28%
2026-03-093.20%
2026-03-063.25%
2026-03-053.26%
2026-03-043.29%
2026-03-033.29%
2026-03-023.35%
2026-02-273.39%
2026-02-263.42%
2026-02-253.50%
2026-02-243.46%
2026-02-233.44%
2026-02-203.37%
2026-02-193.43%
2026-02-183.43%
2026-02-173.58%
2026-02-133.58%
2026-02-123.68%
2026-02-113.61%
2026-02-103.43%
2026-02-092.70%
2026-02-062.64%
2026-02-052.64%
2026-02-042.55%
2026-02-032.52%
2026-02-022.43%
2026-01-302.46%
2026-01-292.41%
2026-01-282.39%
2026-01-272.38%
2026-01-262.38%
2026-01-232.43%
2026-01-222.36%
2026-01-212.31%
2026-01-202.38%
2026-01-162.34%
2026-01-152.32%
2026-01-142.32%
2026-01-132.35%
2026-01-122.39%
2026-01-092.41%
2026-01-082.38%
2026-01-072.33%
2026-01-062.35%
2026-01-052.44%
2026-01-022.51%
2025-12-312.55%
2025-12-302.52%
2025-12-292.51%
2025-12-262.52%
2025-12-242.50%
2025-12-232.51%
2025-12-222.50%
2025-12-192.52%
2025-12-182.55%
2025-12-172.57%
2025-12-162.56%
2025-12-152.56%
2025-12-122.56%
2025-12-112.53%
2025-12-102.55%
2025-12-092.63%
2025-12-082.61%
2025-12-052.61%
2025-12-042.63%
2025-12-032.48%
2025-12-022.45%
2025-12-012.43%
2025-11-282.42%
2025-11-262.36%
2025-11-252.34%
2025-11-242.31%
2025-11-212.42%
2025-11-202.44%
2025-11-192.42%
2025-11-182.42%
2025-11-172.44%
2025-11-142.42%
2025-11-132.42%
2025-11-122.39%
2025-11-112.37%
2025-11-102.38%
2025-11-072.43%
2025-11-062.42%
2025-11-052.39%
2025-11-042.41%
2025-11-032.41%
2025-10-312.45%
2025-10-302.47%
2025-10-292.45%
2025-10-282.46%
2025-10-272.40%
2025-10-242.36%
2025-10-232.40%
2025-10-222.46%
2025-10-212.46%
2025-10-202.47%
2025-10-172.55%
2025-10-162.58%
2025-10-152.62%
2025-10-142.60%
2025-10-132.55%
2025-10-102.68%
2025-10-092.59%
2025-10-082.53%
2025-10-072.53%
2025-10-062.54%
2025-10-032.53%
2025-10-022.51%
2025-10-012.47%
2025-09-302.62%
2025-09-292.69%
2025-09-262.71%
2025-09-252.76%
2025-09-242.70%
2025-09-232.71%
2025-09-222.70%
2025-09-192.70%
2025-09-182.68%
2025-09-172.70%
2025-09-162.74%
2025-09-152.71%
2025-09-122.74%
2025-09-112.70%
2025-09-102.82%
2025-09-092.77%
2025-09-082.73%
2025-09-052.76%
2025-09-042.79%
2025-09-032.79%
2025-09-022.84%
2025-08-292.83%
2025-08-282.84%
2025-08-272.84%
2025-08-262.87%
2025-08-252.88%
2025-08-222.90%
2025-08-212.97%
2025-08-202.89%
2025-08-192.91%
2025-08-182.91%
2025-08-152.94%
2025-08-142.93%
2025-08-132.87%
2025-08-122.93%
2025-08-112.99%
2025-08-083.10%
2025-08-073.14%
2025-08-063.13%
2025-08-053.08%
2025-08-043.11%
2025-08-013.18%
2025-07-313.15%
2025-07-303.07%
2025-07-293.00%
2025-07-282.97%
2025-07-253.01%
2025-07-242.95%
2025-07-233.08%
2025-07-222.82%
2025-07-214.24%
2025-07-184.20%
2025-07-174.11%
2025-07-164.16%
2025-07-154.19%
2025-07-144.09%
2025-07-114.05%
2025-07-103.99%
2025-07-094.08%
2025-07-084.06%
2025-07-074.11%
2025-07-034.07%
2025-07-024.02%
2025-07-014.08%
2025-06-304.17%
2025-06-274.22%
2025-06-264.27%
2025-06-254.21%
2025-06-244.15%
2025-06-234.24%
2025-06-204.23%
2025-06-184.33%
2025-06-174.40%
2025-06-164.35%
2025-06-134.39%
2025-06-124.31%
2025-06-114.33%
2025-06-104.28%
2025-06-094.39%
2025-06-064.42%
2025-06-054.46%
2025-06-044.19%

Showing the most recent 260 of 2,416 data points. The chart above shows the full history.

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Cincinnati, OH
5,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
August James Troendle